School of Pharmacy, University of Otago, PO Box 56, Dunedin, New Zealand.
New Zealand Pharmacovigilance Centre, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Drug Saf. 2019 Dec;42(12):1449-1469. doi: 10.1007/s40264-019-00854-x.
There is increasing evidence to suggest that therapeutic doses of metformin are unlikely to cause lactic acidosis. The aims of this research were (1) to formally evaluate the association between metformin therapy and lactic acidosis in published case reports using two causality scoring systems, (2) to determine the frequency of pre-existing independent risk factors in published metformin-associated lactic acidosis cases, (3) to investigate the association between risk factors and mortality in metformin-associated lactic acidosis cases, and (4) to explore the relationship between prescribed metformin doses, elevated metformin plasma concentrations and the development of lactic acidosis in cases with chronic renal impairment.
A systematic review was conducted to identify metformin-associated lactic acidosis cases. Causality was assessed using the World Health Organisation-Uppsala Monitoring Centre system and the Naranjo adverse drug reaction probability scale. Compliance to dosing guidelines was investigated for cases with chronic renal impairment as well as the association between steady-state plasma metformin concentrations prior to admission.
We identified 559 metformin-associated lactic acidosis cases. Almost all cases reviewed (97%) presented with independent risk factors for lactic acidosis. The prescribed metformin dose exceeded published guidelines in 60% of cases in patients with impaired kidney function. Metformin steady-state plasma concentrations prior to admission were predicted to be below the proposed upper limit of the therapeutic range of 5 mg/L.
Almost all cases of metformin-associated lactic acidosis reviewed presented with independent risk factors for lactic acidosis, supporting the suggestion that metformin plays a contributory role. The prescribed metformin dose, on average, exceeded the dosing recommendations by 1000 mg/day in patients with varying degrees of renal impairment but the predicted pre-admission plasma concentrations did not exceed the therapeutic range.
越来越多的证据表明,治疗剂量的二甲双胍不太可能导致乳酸酸中毒。本研究的目的是(1)使用两种因果关系评分系统,正式评估已发表的病例报告中二甲双胍治疗与乳酸酸中毒之间的关联,(2)确定已发表的二甲双胍相关乳酸酸中毒病例中预先存在的独立危险因素的频率,(3)研究二甲双胍相关乳酸酸中毒病例中危险因素与死亡率之间的关联,以及(4)探索慢性肾功能不全患者中规定的二甲双胍剂量、升高的二甲双胍血浆浓度与乳酸酸中毒发展之间的关系。
系统检索了二甲双胍相关乳酸酸中毒病例。使用世界卫生组织-乌普萨拉监测中心系统和 Naranjo 药物不良反应概率量表评估因果关系。调查了慢性肾功能不全患者的剂量依从性以及入院前稳态血浆二甲双胍浓度与乳酸酸中毒发展之间的关系。
我们确定了 559 例二甲双胍相关乳酸酸中毒病例。几乎所有回顾的病例(97%)都存在乳酸酸中毒的独立危险因素。肾功能受损患者中,60%的病例规定的二甲双胍剂量超过了已发表的指南。入院前的二甲双胍稳态血浆浓度预计低于提出的治疗范围上限 5mg/L。
几乎所有回顾的二甲双胍相关乳酸酸中毒病例均存在乳酸酸中毒的独立危险因素,这支持了二甲双胍起促成作用的观点。在肾功能不同程度受损的患者中,规定的二甲双胍剂量平均超过了剂量推荐值 1000mg/天,但预测的入院前血浆浓度并未超过治疗范围。